Clinuvel Pharmaceuticals Ltd (CUV)

41.71
+0.61(+1.48%)
  • Volume:
    391,331
  • Bid/Ask:
    41.70/41.71
  • Day's Range:
    39.59 - 42.00

CUV Overview

Prev. Close
41.1
Day's Range
39.59-42
Revenue
71.17M
Open
40.09
52 wk Range
19.63-42.2
EPS
0.47
Volume
391,331
Market Cap
2.03B
Dividend (Yield)
0.03
(0.06%)
Average Volume (3m)
146,984
P/E Ratio
86.79
Beta
0.38
1-Year Change
70.6%
Shares Outstanding
49,410,338
Next Earnings Date
-
What is your sentiment on Clinuvel Pharmaceuticals Ltd?
or
Market is currently closed. Voting is open during market hours.

Clinuvel Pharmaceuticals Ltd News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

Clinuvel Pharmaceuticals Ltd Company Profile

Clinuvel Pharmaceuticals Ltd Company Profile

Employees
16
Market
Australia

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People’s Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Read More
  • u want it? 35
    0
    • prudent
      0
      • lie they are very prudent
        0
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.